

16

RECEIVED

AUG 29 2002

TECH CENTER 1600/2900

PATENT

RCE/\$  
1600#17  
MP  
9/5/02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, J.

For: New Pharmaceutical Composition And The Process For Its Preparation

Confirmation No.: 7926

## REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents  
Box RCE  
Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above identified application.

## 1. Submission required under 37 C.F. R. § 1.114

a. ☐ Previously submitted

- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

b. ☒ Enclosed

- i. ☒ Amendment / Reply
- ii. ☒ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other-Substitute Specification

00/20/2002 RCE/1 00000163 141447 09450609

01 FC:179  
02 FC:120740.00 CH  
1850.00 CH

2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of \_\_\_\_\_ months. (period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17 (i) required)

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account 14-1447.

4. Fees

☒ The Director is hereby authorized to charge the following fees, any extra fees, or credit any overpayments, to Deposit **Account No. 14-1447**.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e) of \$740.00
- ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) of 5 months for \$1,960.00
- iii. ☐ Other

A duplicate of this sheet is enclosed.

Date:

8/23/02

Respectfully submitted,



Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for Novo Nordisk  
of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123


RECEIVED

AUG 29 2002

PATENT

TECH CENTER 1600/2900

Attorney Docket No.: 5739.200-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Application No.: 09/450,609

Group Art Unit: 1617

Filed: November 30, 1999

Examiner: Kim, J.

For: New Pharmaceutical Composition And The Process For Its Preparation

Confirmation No.: 7926

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Assistant Commissioner for Patents

Washington, DC 20231

Box RCE

Sir:

I hereby certify that the attached correspondence comprising:

- RCE Transmittal (in duplicate)
- Amendment
- Declaration Under 37 C.F.R. 1.132
- Substitute Specification (clean version and marked up version)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on August 23, 2002

Cheryl H. Agris  
(name of person mailing paper)

Cheryl H. Agris  
(signature of person mailing paper)